# Axcelis Technologies Inc: Form 10-Q for the period ended Mar 31, 2020

- Company: [Axcelis Technologies Inc](/companies/acls.md) (CIK 1113232)
- Form: 10-Q
- Filed: 2020-05-06
- Accepted by EDGAR: May 6, 2020, 11:46 ET
- Period: 2020-03-31
- Accession: 0001558370-20-005335
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1113232/000155837020005335/acls-20200331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1113232/000155837020005335/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $119.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $73.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-01-01 to 2020-03-31 | $45.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $14.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | $13.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-01-01 to 2020-03-31 | $1.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | $11.2m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | $0.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-01-01 to 2020-03-31 | $0.34 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-01-01 to 2020-03-31 | 34,057,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | $39.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2020-01-01 to 2020-03-31 | $7.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-03-31 | $174.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $391.7m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $562.6m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $75.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $135.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-03-31 | $427.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 24,004 characters.

*Certain statements within "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements that involve risks and uncertainties. Words such as may, will, should, would, anticipates, expects, intends, plans, believes, seeks, estimates and similar expressions identify such forward-looking statements. The forward-looking statements contained herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Factors that might cause such a difference include, among other things, those set forth under "Liquidity and Capital Resources" below and under “Risk Factors” in Part I, Item 1A to our annual report on Form 10-K for the year ended December 31, 2019* and in Part II, Item 1A to this report on Form 10-Q, which discussion is incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting forward-looking statements, except as may be required by law.

### Overview

We are primarily a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition, we provide extensive worldwide aftermarket service and support, including spare parts, equipment upgrades and maintenance services to the semiconductor industry. Our product development and manufacturing activities occur primarily in the United States. Our equipment and service products are highly technical and are sold through a direct sales force in the United States, Europe and Asia. Consolidation and partnering within the semiconductor manufacturing industry has resulted in a small number of customers representing a substantial portion of our business. Our ten largest customers accounted for 85.9% of total revenue for the three months ended March 31, 2020.

In the first three months of 2020, we delivered strong financial performance driven by demand for our Purion systems. The semiconductor supply chain was identified as a critical infrastructure sector in the Advisory Memorandum issued by the U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (“CISA”) on March 19, 2020 and updated on March 28, 2020. CISA’s list has been incorporated in orders by the Governor of Massachusetts and other states, which urge critical infrastructure sector businesses to continue to operate during the COVID-19 pandemic. Axcelis has continued to operate during this time, with a combination of work from home and the implementation of protocols for social distancing and other practices in our facilities, as recommended by the U.S. Centers for Disease Control and Prevention. Business travel has been substantially curtailed. Operations outside of the U.S. have also been conducted in accordance with applicable local governmental laws and public health recommendations. We are closely monitoring the impact of the pandemic on our business and will adjust operations as needed.

The ultimate consequence of the pandemic on the semiconductor industry will be the aggregation of both positive and negative forces on various customer market segments. For example, the pandemic may drive enhanced investment in PCs, video streaming and communications technologies. On the other hand, it is dampening the demand for semiconductors for automotive and aviation applications. Our customers will be adapting to the changes in the volumes of different types of semiconductors demanded by the market. These adaptations could cause delay and uncertainty that could impact Axcelis. However, we are working closely with our customers across market segments, even during this difficult time, to provide them with the best ion implant solutions for their specific manufacturing challenges.

The currently implemented, and potential additional, disruptions and restrictions on our operations and ability to travel, and similar disruptions and restrictions impacting our suppliers or customers, could adversely affect our sales and operating results. Axcelis’ products rely on an extensive global supply chain, and shortages of certain parts could impact our ability to meet customer’s shipment expectations, negatively affecting our revenues. The COVID-19 pandemic may drive changes in the demand for certain of our customers’ products, resulting in their delay or cancelation of purchases from us. The extent to which the COVID-19 coronavirus may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including the severity of the coronavirus and the duration of the current pandemic.

### Critical Accounting Estimates

Management’s discussion and analysis of our financial condition and results of operations included herein and in our Annual Report on Form 10-K for the year ended December 31, 2019 are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and assumptions. Management’s estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Management has not identified any need to make any material change in, and has not changed, any of our critical accounting estimates and judgments as described in Management’s Discussion and Analysis of Financial Conditions and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2019.

### Results of Operations

The following table sets forth our results of operations as a percentage of total revenue:

| Revenue: | Three months ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Product | 94.2% | 92.0% |
| Services | 5.8 | 8.0 |
| Total revenue | 100.0 | 100.0 |
| Cost of revenue: |  |  |
| Product | 56.5 | 51.7 |
| Services | 5.3 | 7.3 |
| Total cost of revenue | 61.8 | 59.0 |
| Gross profit | 38.2 | 41.0 |
| Operating expenses: |  |  |
| Research and development | 12.3 | 15.0 |
| Sales and marketing | 6.9 | 9.7 |
| General and administrative | 7.6 | 8.5 |
| Total operating expenses | 26.8 | 33.2 |
| Income from operations | 11.4 | 7.8 |
| Other (expense) income: |  |  |
| Interest income | 0.4 | 0.9 |
| Interest expense | (1.1) | (1.3) |
| Other, net | (0.5) | (0.2) |
| Total other expense | (1.2) | (0.6) |
| Income before income taxes | 10.2 | 7.2 |
| Income tax provision | 0.9 | 0.5 |
| Net income | 9.3% | 6.7% |

### Revenue

The following table sets forth our product and services revenue:

*(dollars in thousands)*

| Revenue: | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Product | $112,133 | $84,197 | $27,936 | 33.2% |
| Percentage of revenue | 94.2% | 92.0% |  |  |
| Services | 6,858 | 7,280 | (422) | (5.8)% |
| Percentage of revenue | 5.8% | 8.0% |  |  |
| Total revenue | $118,991 | $91,477 | $27,514 | 30.1% |

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

#### Product

Product revenue, which includes systems sales, sales of spare parts, product upgrades and used systems was $112.1 million, or 94.2% of revenue during the three months ended March 31, 2020, compared with $84.2 million, or 92.0% of revenue for the three months ended March 31, 2019. The $27.9 million increase in product revenue for the three month period ending March 31, 2020, in comparison to the same period in 2019, was primarily driven by an increase in the number of systems sold.

A portion of our revenue from systems sales is deferred until installation and other services related to future performance obligations are performed. The total amount of deferred revenue at March 31, 2020 and December 31, 2019 was $34.1 million and $29.3 million, respectively. The net increase in deferred revenue was primarily due to collection of advance payments on systems.

#### Services

Services revenue, which includes the labor component of maintenance and service contracts and fees for service hours provided by on-site service personnel, was $6.9 million, or 5.8% of revenue for the three months ended March 31, 2020, compared with $7.3 million, or 8.0% of revenue for the three months ended March 31, 2019. Although services revenue typically increases with the expansion of the installed base of systems, it can fluctuate from period to period based on capacity utilization at customers’ manufacturing facilities, which affects the need for equipment service.

### Revenue Categories used by Management

In addition to the line item revenue categories discussed above, management also regularly disaggregates revenue in the following categories, which it finds relevant and useful:

- Ion implant revenue separate from revenue from legacy non-implant product lines, given that ion implantation systems are the primary driver of our growth and strategic objectives;
- Systems and Aftermarket revenues, in which “Aftermarket” is

A. the portion of Product revenue relating to spare parts, product upgrades and used systems combined with

B. Services revenue, which is the labor component of Aftermarket revenues;

Aftermarket purchases reflect current fab utilization as opposed to Systems purchases which reflect capital investment decisions by our customers, which have differing economic drivers;

- Revenue by geographic regions, since economic factors impacting customer purchasing decisions may vary by geographic region; and
- Revenue by our customer market segments, since they can be subject to different economic drivers at different periods of time, impacting a customer’s likelihood of purchasing capital equipment during any particular period. Currently, management references three customer market segments: memory, mature technology processes and leading edge foundry and logic.

The ion implant and Aftermarket revenue categories for recent periods are discussed below.

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

#### Ion Implant

Included in total revenue of $119.0 million during the three months ended March 31, 2020 is revenue from sales of ion implant products and services of $115.0 million, or 96.7% of total revenue, compared with $87.0 million, or 95.1%, of total revenue for the three months ended March 31, 2019. The remaining $4.0 million of revenue for the three months ended March 31, 2020 was non-ion implant parts and services.

#### Aftermarket

Included in total revenue of $119.0 million during the three months ended March 31, 2020 is revenue from our Aftermarket business of $36.7 million, compared to $34.4 million for the three months ended March 31, 2019. The remaining $82.3 million of revenue for the three months ended March 31, 2020 was from system sales. Aftermarket revenue fluctuates from period to period based on capacity utilization at customers’ manufacturing facilities, which affects the sale of spare parts and demand for equipment service. Aftermarket revenue can also fluctuate from period to period based on the demand for system upgrades or used tools.

### Gross Profit / Gross Margin

The following table sets forth our gross profit / gross margin:

*(dollars in thousands)*

| Gross Profit: | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Product | $44,961 | $36,859 | $8,102 | 22.0% |
| Product gross margin | 40.1% | 43.8% |  |  |
| Services | 588 | 647 | (59) | (9.1)% |
| Services gross margin | 8.6% | 8.9% |  |  |
| Total gross profit | $45,549 | $37,506 | $8,043 | 21.4% |
| Gross margin | 38.2% | 41.0% |  |  |

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

#### Product

Gross margin from product revenue was 40.1% for the three months ended March 31, 2020, compared to 43.8% for the three months ended March 31, 2019. The decrease in gross margin resulted from the successful conversion of three evaluation systems into sales during the quarter.

#### Services

Gross margin from services revenue was 8.6% for the three months ended March 31, 2020, compared to 8.9% for the three months ended March 31, 2019. The decrease in gross margin is attributable to changes in the mix of service contracts.

### Operating Expenses

The following table sets forth our operating expenses:

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $14,606 | $13,685 | $921 | 6.7% |
| Percentage of revenue | 12.3% | 15.0% |  |  |
| Sales and marketing | 8,204 | 8,918 | (714) | (8.0)% |
| Percentage of revenue | 6.9% | 9.7% |  |  |
| General and administrative | 9,036 | 7,807 | 1,229 | 15.7% |
| Percentage of revenue | 7.6% | 8.5% |  |  |
| Total operating expenses | $31,846 | $30,410 | $1,436 | 4.7% |
| Percentage of revenue | 26.8% | 33.2% |  |  |

Our operating expenses consist primarily of personnel costs, including salaries, commissions, expected incentive plan payouts, stock-based compensation and related benefits and taxes; project material costs related to the design and development of new products and enhancement of existing products; and professional fees, travel and depreciation expenses.

Personnel costs are our largest expense, representing $19.9 million or 62.6% of our total operating expenses for the three month period ended March 31, 2020, compared to $17.8 million or 58.4% of our total operating expenses for the three month period ended March 31, 2019. The higher personnel costs for the three month periods ended March 31, 2020 is primarily due to higher incentive based pay expense.

### Research and Development

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $14,606 | $13,685 | $921 | 6.7% |
| Percentage of revenue | 12.3% | 15.0% |  |  |

Our ability to remain competitive depends largely on continuously developing innovative technology, with new and enhanced features and systems and introducing them at competitive prices on a timely basis. Accordingly, based on our strategic plan, we establish annual R&D budgets to fund programs that we expect will solve customers’ high value, high impact, ion implantation challenges.

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

Research and development expense was $14.6 million during the three months ended March 31, 2020, an increase of $0.9 million, or 6.7%, compared with $13.7 million during the three months ended March 31, 2019. The increase is primarily due to higher incentive based pay expense and increased depreciation associated with capital additions.

### Sales and Marketing

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Sales and marketing | $8,204 | $8,918 | $(714) | (8.0)% |
| Percentage of revenue | 6.9% | 9.7% |  |  |

Our sales and marketing expenses result primarily from the sale of our equipment and services through our direct sales force.

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

Sales and marketing expense was $8.2 million during the three months ended March 31, 2020, a decrease of $0.7 million, or 8.0%, compared with $8.9 million during the three months ended March 31, 2019. The decrease is primarily due to reduced tariffs.

### General and Administrative

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-Period Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| General and administrative | $9,036 | $7,807 | $1,229 | 15.7% |
| Percentage of revenue | 7.6% | 8.5% |  |  |

Our general and administrative expenses result primarily from the costs associated with our executive, finance, information technology, legal and human resource functions.

#### Three months ended March 31, 2020 Compared with Three months ended March 31, 2019

General and administrative expense was $9.0 million during the three months ended March 31, 2020, an increase of $1.2 million, or 15.7%, compared with $7.8 million during the three months ended March 31, 2019. The increase is primarily due to an increase in incentive based pay expense.

### Other (Expense) Income

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-period change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Other expense | $(1,441) | $(562) | $(879) | (156.4)% |
| Percentage of revenue | (1.2)% | (0.6)% |  |  |

Other (expense) income consists primarily of interest expense relating to the finance lease obligation we incurred in connection with the 2015 sale of our headquarters facility and other financing obligations, foreign exchange gains and losses attributable to fluctuations of the US dollar against local currencies of certain of the countries in which we operate as well as interest earned on our invested cash balances.

Other expense was $1.4 million for the three months ended March 31, 2020, compared with $0.6 million for the three months ended March 31, 2019. The increase in other expense of $0.9 million for the three month period ended March 31, 2020 compared to the three month period ended March 31, 2019, was primarily due to higher foreign currency exchange losses in the current year period compared to the prior year.

During the three month periods ended March 31, 2020 and 2019, we had no significant off-balance-sheet risk such as exchange contracts, option contracts or other hedging arrangements.

### Income Tax Provision

*(dollars in thousands)*

|  | Three months ended March 31, 2020 | 2019 | Period-to-period change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Income tax provision | $1,041 | $472 | $569 | 120.6% |
| Percentage of revenue | 0.9% | 0.5% |  |  |

24

Income tax expense was $1.0 million for the three months ended March 31, 2020, compared to $0.5 million the three months ended March 31, 2019. The $0.5 million increase was primarily due to a $5.7 million increase in pretax income, which was slightly offset by excess tax benefits associated with stock option exercises for the three months ended March 31, 2020, compared to the three months ended March 31, 2019.

We had $66.6 million and $68.1 million of net deferred tax assets worldwide relating to net operating loss carryforwards, tax credit carryforwards and other temporary differences, as of March 31, 2020 and December 31, 2019, respectively. These deferred tax assets are available to reduce income taxes in future years. We have a $9.1 million valuation allowance in the U.S. against certain tax credits and state net operating losses due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these tax assets. If future operating results of the U.S. or these foreign jurisdictions are significantly less than our expectations, it is reasonably possible that we would be required to record an additional valuation allowance on our deferred tax assets in the future.

### Liquidity and Capital Resources

We had $174.7 million in unrestricted cash and cash equivalents at March 31, 2020, in addition to $6.7 million in restricted cash, primarily comprised of the $5.9 million security for the lease of our corporate headquarters. Management believes that maintaining a strong cash balance is necessary to provide funding for potential ramps in our business which can require significant cash investment to meet sudden demand. Additionally, we are considering both organic and inorganic opportunities to drive future growth, for which cash resources will be necessary.

Our liquidity is affected by many factors. Some of these relate specifically to the operations of our business, for example, the rate of sale of our products, and others relate to the uncertainties of global economic conditions, including the availability of credit and the condition of the overall semiconductor equipment industry. Our established cost structure, other than cost of goods sold, does not vary significantly with changes in volume. We experience fluctuations in operating results and cash flows depending on these factors. We may also engage in stock repurchases, as discussed below.

During the three months ended March 31, 2020, we generated $39.7 million of cash related to operating activities. In comparison, during the three months ended March 31, 2019, we used $12.3 million of cash from operations.

Investing activities for the three months ended March 31, 2020 and 2019 resulted in cash outflows of $1.3 million and $4.3 million, respectively, used for capital expenditures.

Financing activities for the three months ended March 31, 2020 resulted in a net cash usage of $4.1 million. During the quarter, $7.5 million in cash was used to repurchase common stock and $1.2 million was used for payments to government tax authorities for income tax withholding on RSU vesting, where shares are withheld by the Company. These amounts were partially offset by $4.5 million of proceeds from the exercise of stock options and purchases under the ESPP. Financing activities for the three months ended March 31, 2019 generated net cash of $1.5 million, of which $1.8 million related to the exercise of stock options, partially offset by $0.3 million related to payments made to government tax authorities for income tax withholding on RSU vesting.

We believe that based on our current market, revenue, expense and cash flow forecasts, our existing cash, cash equivalents and borrowing capacity will be sufficient to satisfy our anticipated cash requirements for the short and long-term. We currently have no credit facility but management believes we would be able to borrow if needed.

In December 2019, our Board of Directors authorized an increase and extension of the share repurchase program, of up to $50 million of the Company's common stock through 2020. These shares could be purchased in the open market or through privately negotiated transactions. As of March 31, 2020, we had approximately $24.8 million remaining under the share repurchase program but have suspended the repurchase program while we continue to invest in the business during these difficult times. See Part II, Item 2 of this report for purchases under this program. The timing and actual number of shares repurchased in 2020 will depend on various factors, including the price of our common stock, general business and market conditions, and alternative investment opportunities. Consideration of each of these factors will include an evaluation of the known and anticipated effects of the COVID-19 pandemic on our business and industry. See Note 15 to the financial statements above.

### Commitments and Contingencies

Significant commitments and contingencies at March 31, 2020 are consistent with those discussed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 16 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

## Market risk

As filed, 200 characters.

As of March 31, 2020, there have been no material changes to the quantitative information about market risk disclosed in Item 7A to our annual report on Form 10-K for the year ended December 31, 2019.

## Controls and procedures

As filed, 1,033 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report (the “Evaluation Date”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the Evaluation Date, these disclosure controls and procedures are effective.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the three months ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,673 characters.

As of March 31, 2020, there have been no material changes to the risk factors described in Item 1A to our annual report on Form 10-K for the year ended December 31, 2019, other than the addition of the risk factor set forth below.

***Our financial condition and results of operations could be adversely affected by the recent coronavirus outbreak.*** The novel strain of coronavirus which causes the illness referred to as COVID-19, as with other contagious diseases or other adverse public health developments, may have a material and adverse effect on our business operations. In the case of COVID-19, governmental orders and employee health and safety concerns have caused Axcelis to continue its operations using a combination of work from home and social distancing protocols in our facilities. Business travel has also been substantially curtailed. These and potential other disruptions or restrictions on our operations and ability to travel, and similar disruptions and restrictions impacting our suppliers or customers could adversely affect our sales and operating results. Axcelis’ products rely on an extensive global supply chain, and shortages of certain parts could impact our ability to meet customer’s shipment expectations, negatively affecting our revenues. The COVID-19 pandemic may drive changes in the demand for certain of our customers’ products, resulting in their delay or cancelation of purchases from us. The extent to which the COVID-19 coronavirus may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including the severity of the coronavirus and the duration of the current pandemic.

Filed May 6, 2020.
Source: SEC EDGAR, the filing index for accession 0001558370-20-005335. Last ingested by Listed: Nov 13, 2026, 17:24 ET. No prices; not investment advice.
